Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riccardo Patacchini

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
The Journal of Pharmacology and Experimental Therapeutics|January 11, 2015
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administrationNadia Moretto, Paola Caruso, Raffaella Bosco, et al.
Journal of Medicinal Chemistry|June 10, 2024
Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Inhaled Treatment of Respiratory DiseasesLaura Carzaniga, Ian D Linney, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|December 5, 2017
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory DiseasesLaura Carzaniga, Gabriele Amari, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|May 13, 2022
Design, Synthesis, and Biological Characterization of Inhaled p38α/β MAPK Inhibitors for the Treatment of Lung Inflammatory DiseasesElisabetta Armani, Carmelida Capaldi, Valentina Bagnacani, et al.
Journal of Medicinal Chemistry|August 10, 2023
Optimization of M<sub>3</sub> Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPDAndrea Rizzi, Gabriele Amari, Fausto Pivetti, et al.
Journal of Medicinal Chemistry|June 18, 2021
Discovery of M<sub>3</sub> Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary DiseaseElisabetta Armani, Andrea Rizzi, Carmelida Capaldi, et al.
Journal of Medicinal Chemistry|January 10, 2014
Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseasesElisabetta Armani, Gabriele Amari, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|March 14, 2007
Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 2)Ilaria Peretto, Claudia Fossati, Giuseppe A M Giardina, et al.
Journal of Medicinal Chemistry|July 28, 2022
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Inhaled Treatment of Respiratory DiseasesLaura Carzaniga, Ian D Linney, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|March 14, 2007
Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1)Ilaria Peretto, Roberto Forlani, Claudia Fossati, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
The Journal of Pharmacology and Experimental Therapeutics|January 11, 2015
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administrationNadia Moretto, Paola Caruso, Raffaella Bosco, et al.
Journal of Medicinal Chemistry|June 10, 2024
Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Inhaled Treatment of Respiratory DiseasesLaura Carzaniga, Ian D Linney, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|December 5, 2017
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory DiseasesLaura Carzaniga, Gabriele Amari, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|May 13, 2022
Design, Synthesis, and Biological Characterization of Inhaled p38α/β MAPK Inhibitors for the Treatment of Lung Inflammatory DiseasesElisabetta Armani, Carmelida Capaldi, Valentina Bagnacani, et al.
Journal of Medicinal Chemistry|August 10, 2023
Optimization of M<sub>3</sub> Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPDAndrea Rizzi, Gabriele Amari, Fausto Pivetti, et al.
Journal of Medicinal Chemistry|June 18, 2021
Discovery of M<sub>3</sub> Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary DiseaseElisabetta Armani, Andrea Rizzi, Carmelida Capaldi, et al.
Journal of Medicinal Chemistry|January 10, 2014
Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseasesElisabetta Armani, Gabriele Amari, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|March 14, 2007
Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 2)Ilaria Peretto, Claudia Fossati, Giuseppe A M Giardina, et al.
Journal of Medicinal Chemistry|July 28, 2022
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Inhaled Treatment of Respiratory DiseasesLaura Carzaniga, Ian D Linney, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|March 14, 2007
Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1)Ilaria Peretto, Roberto Forlani, Claudia Fossati, et al.
Pageof 6